New treatment path for Tetralogy of Fallot, a congenital pediatric heart disease that affects one in 4,000 births, and is also called "blue baby disease." It all relies on a new, entirely biological valve created from human collagen with no risk of rejection, unlike the materials used to date.
This work was carried out in collaboration with the Massachusetts Institute of Technology, the famous MIT, and has just been published in the journal Science Translational Medicine. .The team of Fabien Kawecki (University of Bordeaux, Inserm), who has been working on the subject for several years, is proposing a new approach here.
English 
French